FAQ

MK-7009

Known as: MK 7009, MK7009 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
012320092015

Related topics

Related topics

2 relations

Broader (1)

Indoles
vaniprevir

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
MK-7009
Indoles
vaniprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.
BACKGROUND Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2013
2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
BACKGROUND & AIMS MK-7009 (vaniprevir) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
UNLABELLED Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2012
2012
Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
A highly efficient synthesis of Vaniprevir (MK-7009) has been accomplished in nine linear steps and 55% overall yield. The key… (More)
Is this relevant?
2011
2011
Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.
Development of a practical synthesis of MK-7009, a 20-membered [corrected] macrocycle, is described. A variety of ring-closing… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
BACKGROUND & AIMS The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2011
2011
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.
Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are contingent on the… (More)
  • figure 2
  • figure 1
Is this relevant?
2010
2010
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
The administration of hepatitis C virus (HCV) NS3/4A protease inhibitors to patients with chronic HCV infections has demonstrated… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2010
2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2010
2010
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs) among… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?